Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.41 |
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CFB | P00751 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673565 | 0.94 | SPHK2 (0.45) | SPHK2SPHK1TERTPOLBL3MBTL1 | |
| SCHEMBL10688068 | 0.94 | SPHK2 (0.45) | SPHK2SPHK1TERTPOLBL3MBTL1 | |
| SCHEMBL1023833 | 0.94 | SPHK2 (0.45) | SPHK2SPHK1TERTPOLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL31323595 | 0.92 | SPHK2 (0.44) | SPHK2SPHK1TERTPOLBL3MBTL1 | |
| SCHEMBL10867079 | 0.87 | SPHK2 (0.45) | SPHK2SPHK1TERTALDH1A1POLB | |
| SCHEMBL3426506 | 0.83 | SPHK2 (0.43) | SPHK2SPHK1TERTALDH1A1POLB | |
| SCHEMBL2672892 | 0.82 | SPHK2 (0.47) | SPHK2SPHK1POLBL3MBTL1S1PR1 | |
| SCHEMBL2672891 | 0.82 | SPHK2 (0.47) | SPHK2SPHK1POLBL3MBTL1S1PR1 | |
| SCHEMBL10687856 | 0.82 | SPHK2 (0.47) | SPHK2SPHK1POLBL3MBTL1S1PR1 | |
| SCHEMBL10706159 | 0.82 | S1PR1 (0.39) | TERTS1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849024-A | With as indoleamine 2, the benzimidazole and imidazopyridine imido of 3 dioxygenase inhibitor activities are for benzamide compound | 吉利德科学公司 | 2018-03-27 | — | — | CN | claimed |
| EP-3294732-B1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| CN-107849024-A | With as indoleamine 2, the benzimidazole and imidazopyridine imido of 3 dioxygenase inhibitor activities are for benzamide compound | 吉利德科学公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-3294732-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Gilead Sciences, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016186967-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GILEAD SCIENCES, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-7557215-B2 | Anthraquinone compounds as anti cancer compounds | SOMANTA LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| EP-1701939-B1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008062252-A1 | N-OXIDES OF CYTOTOXIC ANTHRAQUINONES AS HYPOXIA-TARGETING PRODRUGS IN CANCER TREATMENT | ACCESS PHARMACEUTICALS, INC (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | SOMANTA LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| CN-1934079-A | Anthraquinone compounds as anti cancer compounds | SOMANTA LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
| EP-1701939-A1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | Somanta Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061453-A1 | ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | TOP2A, TOP2B, RECQL | SPHK2 1426/4885SPHK1 1730/4885TERT 3152/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | SPHK2 2504/4885SPHK1 2460/4885TERT 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.